Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04722068
Other study ID # 1331-Kin
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 7, 2016
Est. completion date January 1, 2021

Study information

Verified date May 2021
Source University of Pennsylvania
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To evaluate the lipoprotein kinetics of subjects enrolled in the R1500-CL-1331 clinical trial (NCT02265952) to assess the mechanism by which the evinacumab may affect lipid levels in HoFH subjects.


Description:

Subjects enrolled in the R1500-CL-1331 clinical trial (NCT0226595) will participate in a study visit before and after administration of the ANGPTL3 inhibitor REGN1500, evinacumab) for the evaluation of its effect on lipoprotein kinetics.


Recruitment information / eligibility

Status Completed
Enrollment 4
Est. completion date January 1, 2021
Est. primary completion date November 30, 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Eligibility criteria: -Eligibility will be made based on the data collected at the screening visit of the R1500-CL-1331 protocol. Subjects must meet all inclusion/exclusion criteria for eligibility of that study to be eligible to participate in this sub-study. Below is the eligibility criteria for R1500-CL-1331. Inclusion: - Men and women 18 years or older at the time of the screening visit - Diagnosis of HoFH by one of the following: 1. Documented mutation or mutations in both LDLR alleles 2. Documented presence of homozygous or compound heterozygous mutations in Apo B and/or PCSK9 3. Documented skin fibroblast LDLR activity <20% of normal - Willing to consistently maintain his/her usual diet for the duration of the study - Willing and able to comply with clinic visits and study-related procedures - Provide signed informed consent Exclusion: - Background medical LMT (if applicable) that has not been stable for at least 4 weeks (6 weeks for fibrates) prior to the screening visit (week -2) (unless participating in the run-in period to stabilize) - Having undergone lipid apheresis within 4 weeks prior to the screening visit (week -2) (unless participating in the run-in period to wash out) - Presence of any clinically significant uncontrolled endocrine disease known to influence serum lipids or lipoproteins. Note: Patients on thyroid replacement therapy can be included if the dosage of thyroxine has been stable for at least 12 weeks prior to screening visit (week -2) - Use of systemic corticosteroids, unless used as replacement therapy for pituitary/adrenal disease with a stable regiment for at least 6 weeks prior to the screening visit (week -2) Note: Topical, intra-articular, nasal, inhaled, and ophthalmic steroid therapies are not considered as "systemic" and are allowed - History of a myocardial infarction, unstable angina leading to hospitalization, coronary bypass graft surgery, percutaneous coronary intervention, uncontrolled cardiac arrhythmia, carotid surgery or stenting, stroke, transient ischemic attack, carotid revascularization, endovascular procedure or surgical intervention for peripheral vascular disease within 3 months prior to the screening visit (week -2) - Known history of HIV and a CD4 count less than 350c/mL Note: Patients with a history of HIV can be included, as long as they: 1. have a CD4 count greater than 350c/mL; 2. have an undetectable viral load for at least 12 months prior to screening; 3. have no opportunistic infections or active tuberculosis for at least 12 months prior to screening; 4. are not receiving prophylaxis for opportunistic infections; and have been on stable antiretroviral therapy for at least 12 months prior to screening - Use of another investigational drug or therapy within 30 days or at least 5 half-lives (whichever is longer) prior to screening visit (week -2). Includes patients who were involved in a prior clinical trial and are not sure of their treatment assignment. - Previous participation in any clinical trial of REGN1500 - Conditions/situation such as: 1. Any clinically significant abnormality identified at the time of screening that, in the judgement of the investigator or any subinvestigator, would preclude safe completion of the study or constrain endpoints assessment; eg. major systemic diseases, patients with short life expectancy 2. Patient considered by the investigator or any subinvestigator as inappropriate for this study for any reason, eg: deemed unable to meet specific protocol requirements, such as scheduled visits. Deemed unable to tolerate injections as per the patient or the investigator. Investigator or any subinvestigator, pharmacist, study coordinator, other study staff or relative thereof directly involved in the conduct of the protocol, etc. Presence of any other conditions (eg, geographic or social), either actual or anticipated, that the investigator feels would restrict or limit the patient's participation for the duration of the study - Laboratory findings during screening period: 1. Positive test for Hepatitis B surface antigen and/or Hepatitis C antibody 2. Positive serum beta-human chorionic gonadotropin or urine pregnancy test in women of childbearing potential 3. Triglycerides greater than 400 mg/dL ( >3.95 mmol/L) (1 repeat lab is allowed) 4. Estimated glomerular filtration rate <30 mL/min/1.73m^2 according to 4-variable Modification of Diet in Renal Disease Study equation (calculated by central lab) 5. Alanine amintransferase (ALT) or aspartate aminotransferase (AST) >3 x the upper limit of normal (ULN) (1 repeat lab is allowed) 6. Creatine phosphokinase (CPK) >3 x ULN (1 repeat lab is allowed) - Known hypersensitivity to monoclonal antibody therapeutics - History of hypersensitivity reaction to doxycycline or similar compound - Pregnant or breast-feeding women - Sexually active men, or women of childbearing potential, who are unwilling to utilize adequate contraception for at least 6 months after the last dose of study drug.

Study Design


Intervention

Other:
Kinetics test
Subjects will participate in two study visits to evaluate lipoprotein kinetics before and after administration of evinacumab.

Locations

Country Name City State
Netherlands Department of Vascular Medicine Amsterdam UMC Amsterdam AZ
United States University of Pennsylvania Philadelphia Pennsylvania

Sponsors (2)

Lead Sponsor Collaborator
University of Pennsylvania Regeneron Pharmaceuticals

Countries where clinical trial is conducted

United States,  Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Fractional catabolic rate (FCR) pools/day First visit to be performed prior to first evinacumab administration; second visit to be performed approximately 4-6 weeks after evinacumab i.v. administration. About 8 weeks between the 2 visits. completion of study, average of 8 weeks
Primary Production rate (PR) of lipoproteins mg/kg/day First visit to be performed prior to first evinacumab administration; second visit to be performed approximately 4-6 weeks after evinacumab i.v. administration. About 8 weeks between the 2 visits. completion of study, average of 8 weeks
See also
  Status Clinical Trial Phase
Terminated NCT00384293 - Carotid IMT (Intima Media Thickening) Study (0524A-041)(TERMINATED) Phase 3
Completed NCT04118348 - Evaluating the Efficacy of Pediatric Lipid Screening Alerts N/A
Completed NCT00000594 - NHLBI Type II Coronary Intervention Study Phase 3
Completed NCT04526457 - Is Family Screening Improved by Genetic Testing of Familial Hypercholesterolemia N/A
Completed NCT01753232 - Safety and Efficacy of the DALI LDL-adsorber and MONET Lipoprotein Filter N/A
Completed NCT03018678 - Screening Protocol for a Gene Therapy Trial in Subjects With Homozygous Familial Hypercholesterolemia
Completed NCT00134511 - Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Patients With Genetic High Cholesterol Disorder Phase 3
Completed NCT00134485 - Study To Evaluate The Safety And Efficacy Of Torcetrapib/Atorvastatin In Subjects With Familial Hypercholerolemia Phase 3
Recruiting NCT04073797 - PET Imaging of Inflammation and Lipid Lowering Study N/A
Terminated NCT01583647 - A Study of Extended-release (ER) Niacin/Laropiprant in Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0524A-158) Phase 1
Completed NCT00515307 - Bone Marrow Stem Cells as a Source of Allogenic Hepatocyte Transplantation in Homozygous Familial Hypercholesterolemia Phase 1
Recruiting NCT04656028 - Genetic Testing and Motivational Counseling for FH N/A
Terminated NCT00092833 - Investigational Drug in Patients With Hypercholesterolemia or in Patients With Sitosterolemia (0653-026)(COMPLETED) Phase 3
Active, not recruiting NCT04837638 - Diet Quality and Coronary Artery Calcification in Adults With Heterozygous Familial Hypercholesterolemia
Completed NCT00280995 - Dose-escalating Safety Study of ISIS 301012 in Homozygous Familial Hypercholesterolemia Subjects on Lipid Lowering Therapy Phase 2
Completed NCT06231459 - Expression of Pro- and Anti-inflammatory Cytokines During Anti-PCSK9 in Familial Hypercholesterolemia Phase 4
Completed NCT01524289 - Study to Assess the Tolerability and Efficacy of Anacetrapib (MK-0859) Co-Administered With Statin in Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-020) Phase 3
Completed NCT00281008 - Study of ISIS 301012 (Mipomersen) in Heterozygous Familial Hypercholesterolemia Subjects on Lipid Lowering Therapy Phase 2
Recruiting NCT03989167 - Clinical Decision Support for Familial Hypercholesterolemia N/A
Completed NCT03795038 - Comparison of the Plasma Lipoprotein Apheresis Systems DIAMED and MONET vs. the Whole Blood Apheresis System DALI N/A